In short
Currently, there is 1 ongoing clinical trial investigating treatment options for dystonic tremor. This trial is evaluating the use of botulinum toxin type A injections to reduce arm tremor in patients with dystonia. The study is being conducted in the Netherlands and aims to identify which clinical and imaging factors predict better treatment outcomes.
Clinical trial locations
Study on Botulinum Toxin Type A for Arm Tremor in Patients with Dystonia
This clinical trial is investigating the effectiveness of botulinum toxin type A in treating arm tremor associated with dystonia. The study uses Dysport 300 E, a muscle relaxant that is injected directly into the affected muscles to help reduce involuntary shaking and trembling.
Who can participate:
- Adults aged 18 years or older
- Individuals with a confirmed diagnosis of dystonic tremor or tremor associated with dystonia
- People experiencing tremor in one or both arms
- Patients who are starting botulinum toxin injections as part of their regular medical care
Who cannot participate:
- Individuals with medical conditions other than dystonic tremor syndrome
- People outside the specified age range
- Individuals belonging to vulnerable populations who may require special protection
- Those not meeting other specific study requirements
What the trial involves:
The study aims to understand how different factors influence the success of botulinum toxin treatment for arm tremor. When participants join, they undergo a comprehensive initial assessment that includes clinical evaluations, electrophysiological testing, ultrasound imaging, and magnetic resonance imaging (MRI). These assessments help researchers understand the characteristics of each person's tremor, including its pattern and intensity, as well as the activity in specific brain circuits related to the tremor.
After the initial assessment, participants receive an injection of Dysport 300 E into the affected arm muscles. The treatment works by blocking nerve signals to the muscles, which helps reduce muscle contractions and tremors. Throughout the study, participants attend regular follow-up appointments where researchers monitor how well the treatment is working. These follow-ups may include additional clinical evaluations and imaging studies.
The investigational drug:
Botulinum toxin type A is a neuromuscular blocking agent that prevents the release of acetylcholine, a chemical messenger responsible for muscle contraction. By blocking this signal, the medication reduces excessive muscle activity, helping to control tremors and muscle spasms. In this study, researchers are exploring which patients benefit most from this treatment and what factors predict better outcomes.
The trial is expected to continue until May 2027, with patient recruitment beginning in late 2024. The findings could help doctors develop more personalized treatment strategies for people living with dystonic tremor in the future.
Summary
Currently, only one clinical trial is actively recruiting patients with dystonic tremor. This study is being conducted in the Netherlands and focuses specifically on botulinum toxin type A as a treatment for arm tremor associated with dystonia. The trial takes a comprehensive approach by combining clinical assessments with advanced imaging techniques to identify which patients are most likely to benefit from this treatment. The research extends until 2027 and may provide valuable insights into optimizing treatment strategies for individuals experiencing this challenging condition.
